Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01083602 · OUTCOME

Time to Response (Greater Than or Equal to PR) Based on Investigator Assessment

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma · Source last updated 2017-12-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Days
Interval / dispersion
Standard Deviation
Time frame
after eight cycyles of treatment (24 weeks)

What was measured

Time to response is defined as the time from the date of first administration of study treatment to the date of first documented evidence of CR or nCR or PR (whichever status is recorded first). Patients who do not have a response of PR or better by the data cut-off date are censored.

Analysis population: FAS

Groups in this outcome

Panobinostat + Bortezomib & Dexamethasone

panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Panobinostat + Bortezomib & Dexamethasone55

Reported measurements

Source class 1
Values in Days · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Panobinostat + Bortezomib & Dexamethasone51.830.92Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        30.92
        value
        51.8
denoms
  1. counts
    1. group Id
      OG000
      value
      55
    units
    Participants
description
Time to response is defined as the time from the date of first administration of study treatment to the date of first documented evidence of CR or nCR or PR (whichever status is recorded first). Patients who do not have a response of PR or better by the data cut-off date are censored.
dispersion Type
Standard Deviation
groups
  1. description
    panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma
    id
    OG000
    title
    Panobinostat + Bortezomib & Dexamethasone
param Type
MEAN
population Description
FAS
reporting Status
POSTED
time Frame
after eight cycyles of treatment (24 weeks)
title
Time to Response (Greater Than or Equal to PR) Based on Investigator Assessment
type
SECONDARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice